Table 1.
Summary estimates for intraocular pressure at 3 months derived from pair-wise meta-analysis based on direct comparisons from 114 trials*
|
Comparison-specific heterogeneity
|
|||||||
|---|---|---|---|---|---|---|---|
| Column 1 | Column 2 | Num. of studies | Mean difference¶ | 95% CI, lower | 95% CI, upper | Tau-squared | I-squared |
| Placebo vs. | |||||||
| Brimonidine | 1 | −2.30 | −3.99 | −0.61 | NA | N A | |
| Betaxolol | 3 | −2.38 | −3.78 | −0.98 | 1.11 | 73% | |
| Levobunolol | 2 | −7.52 | −8.50 | −6.50 | NA | NA | |
| Timolol | 5 | −3.68 | −4.72 | −2.63 | 0.71 | 52% | |
| Levobetaxolol | 1 | −3.00 | −4.53 | −1.47 | NA | NA | |
| Brinzolamide | 2 | −2.17 | −3.23 | −1.10 | 0.00 | 0% | |
| Dorzolamide | 4 | −1.91 | −2.92 | −0.90 | 0.51 | 51% | |
| Bimatoprost | 1 | −4.60 | −5.60 | −3.60 | NA | NA | |
| Unoprostone | 1 | −0.20 | −1.56 | 1.16 | NA | NA | |
| Apraclonidine vs | |||||||
| Timolol | 2 | −0.84 | −3.75 | 2.08 | 3.73 | 84 % | |
| Brimonidine vs | |||||||
| Betaxolol | 1 | 1.94 | 0.84 | 3.04 | NA | N A | |
| Timolol | 4 | 0.17 | −0.70 | 1.03 | 0.55 | 81% | |
| Brinzolamide | 2 | 1.01 | 0.50 | 1.53 | 0.00 | 0% | |
| Latanoprost | 5 | −1.36 | −2.21 | −0.50 | 0.73 | 78% | |
| Travoprost | 1 | −1.20 | −3.77 | 1.37 | NA | NA | |
| Betaxolol vs | |||||||
| Levobunolol | 2 | −4.73 | −10.01 | 0.55 | 12.25 | 83% | |
| Timolol | 9 | −1.57 | −2.20 | −0.93 | 0.33 | 41% | |
| Levobetaxolol | 1 | −2.00 | −3.54 | −0.46 | NA | NA | |
| Dorzolamide | 2 | −0.30 | −0.96 | 0.36 | 0.00 | 0% | |
| Latanoprost | 2 | −1.06 | −2.62 | 0.51 | 0.33 | 25% | |
| Unoprostone | 1 | 0.60 | 0.09 | 1.11 | NA | NA | |
| Carteolol vs | |||||||
| Levobunolol | 1 | −2.90 | −4.59 | −1.22 | NA | N A | |
| Timolol | 4 | 0.03 | −0.61 | 0.68 | 0.11 | 24% | |
| Levobunolol vs | |||||||
| Timolol | 11 | −0.03 | −0.44 | 0.39 | 0.01 | 3% | |
| Timolol vs | |||||||
| Levobetaxolol | 3 | 1.25 | 0.27 | 2.23 | 0.52 | 73% | |
| Brinzolamide | 3 | 1.10 | 0.50 | 1.70 | 0.00 | 0% | |
| Dorzolamide | 7 | 0.94 | 0.41 | 1.47 | 0.22 | 43% | |
| Bimatoprost | 7 | −2.08 | −2.47 | −1.70 | 0.05 | 19% | |
| Latanoprost | 14 | −1.27 | −1.70 | −0.84 | 0.37 | 64% | |
| Travoprost | 6 | −0.90 | −1.27 | −0.52 | 0.00 | 0% | |
| Tafluprost | 1 | −0.30 | −0.72 | 0.12 | NA | NA | |
| Unoprostone | 3 | 1.35 | 0.42 | 2.27 | 0.57 | 86% | |
| Brinzolamide vs | |||||||
| Dorzolamide | 2 | −0.58 | −1.15 | 0.00 | 0.00 | 0% | |
| Dorzolamide vs | |||||||
| Latanoprost | 1 | −2.90 | −3.70 | −2.10 | NA | N A | |
| Bimatoprost vs | |||||||
| Latanoprost | 6 | 0.87 | 0.01 | 1.73 | 0.82 | 76 % | |
| Travoprost | 8 | 0.59 | −0.13 | 1.30 | 0.73 | 74% | |
| Latanoprost vs | |||||||
| Travoprost | 7 | −0.06 | −0.46 | 0.34 | 0.00 | 0% | |
| Tafluprost | 1 | −0.90 | −3.40 | 1.60 | NA | NA | |
| Unoprostone | 6 | 3.07 | 2.51 | 3.63 | 0.01 | 2% | |
*
There are 101 two-arm trials, 12 three-arm trials, and 1 four-arm trial (total 114 trials).
¶
Mean difference is caculated using the intraocular pressure of the drug in column 2- coloum 1.
Glaucoma drugs are expected to lower intraocular pressure, therefore, mean difference > 0 favors the drug in column 1; mean difference < 0 favors the drug in column 2.
Color coding:
